Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Adherium Ltd. ( (AU:ADR) ) has shared an update.
Adherium reported accelerating commercial traction for its Hailie Smartinhaler remote patient monitoring platform, with monthly RPM revenue rising 51% from A$68,000 in December 2025 to A$103,000 in February 2026. Revenue of A$198,000 in January and February has already exceeded the prior quarter’s RPM revenue, supported by a 43% increase in cumulative device shipments and a 53% rise in activations over the first two months of 2026.
The company’s call centre and partnerships, including Allergy Partners, now provide access to about 48,000 insurance-verified asthma patients with compatible inhalers, underscoring the scalability of its RPM model. New U.S. CPT reimbursement codes that lower data thresholds and allow billing for shorter consultations are expected to further boost billing efficiency and growth, reinforcing Adherium’s confidence in reaching its goal of 10,000 RPM patients by the end of 2026 and strengthening its position ahead of key outcomes data from the Intermountain Health iCARE Study.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Ltd. is an Australia-based digital health company focused on respiratory disease management. It develops and commercialises the FDA-cleared Hailie Smartinhaler platform, combining sensor-enabled inhaler devices with a cloud-based system to support remote patient monitoring for asthma and COPD patients, with a growing commercial focus on the U.S. market.
Technical Sentiment Signal: Sell
Current Market Cap: A$10.42M
See more data about ADR stock on TipRanks’ Stock Analysis page.